• Accueil
• tpex
• Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

4.8 (566) · € 21.99 · En Stock

Frontiers Cetuximab-Containing Combinations in Locally Advanced

The dogma of cetuximab in advanced squamous cell carcinoma of the

Cancers, Free Full-Text

Cancers, Free Full-Text

PDF) First-line treatment with chemotherapy plus cetuximab in

First‐line cetuximab + platinum‐based therapy for recurrent

Radiotherapy plus cisplatin or cetuximab in low-risk human

Biomedicines, Free Full-Text

Full article: Cost-effectiveness of pembrolizumab for the first

Pharmaceutics, Free Full-Text

Induction docetaxel, cisplatin, and cetuximab followed by